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Summary
Background Whether addition of fl uorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in 
adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefi t of increased density 
of dosing. We aimed to address these questions in terms of improvements in disease-free survival.
Methods In this 2 × 2 factorial, open-label, phase 3 trial, we enrolled patients aged 18–70 years with operable, node 
positive, early-stage breast cancer from 81 Italian centres. Eligible patients were randomly allocated in a 1:1:1:1 ratio 
with a centralised, interactive online system to receive either dose-dense chemotherapy (administered intravenously 
every 2 weeks with pegfi lgrastim support) with fl uorouracil plus EC-P (FEC-P) or EC-P or to receive standard-interval 
chemotherapy (administered intravenously every 3 weeks) with FEC-P or EC-P. The primary study endpoint was 
disease-free survival, assessed with the Kaplan-Meier method in the intention-to-treat population. Our primary 
comparisons were between dose schedule (every 2 weeks vs every 3 weeks) and dose type (FEC-P vs EC-P). This study 
is registered with ClinicalTrials.gov, number NCT00433420.
Findings Between April 24, 2003, and July 3, 2006, we recruited 2091 patients. 88 patients were enrolled in centres that 
only provided standard-intensity dosing. After a median follow-up of 7·0 years (interquartile range [IQR] 4·5–6·3), 
140 (26%) of 545 patients given EC-P every 3 weeks, 157 (29%) of 544 patients given FEC-P every 3 weeks, 111 (22%) 
of 502 patients given EC-P every 2 weeks, and 113 (23%) of 500 patients given FEC-P every 2 weeks had a disease-free 
survival event. For the dose-density comparison, disease-free survival at 5 years was 81% (95% CI 79–84) in patients 
treated every 2 weeks and 76% (74–79) in patients treated every 3 weeks (HR 0·77, 95% CI 0·65–0·92; p=0·004); 
overall survival rates at 5 years were 94% (93–96) and 89% (87–91; HR 0·65, 0·51–0·84; p=0·001) and for the 
chemotherapy-type comparison, disease-free survival at 5 years was 78% (75–81) in the FEC-P groups and 79% 
(76–82) in the EC-P groups (HR 1·06, 0·89–1·25; p=0·561); overall survival rates at 5 years were 91% (89–93) and 92% 
(90–94; 1·16, 0·91–1·46; p=0·234). Compared with 3 week dosing, chemotherapy every 2 weeks was associated with 
increased rate of grade 3–4 of anaemia (14 [1·4%] of 988 patients vs two [0·2%] of 984 patients; p=0·002); transaminitis 
(19 [1·9%] vs four [0·4%]; p=0·001), and myalgias (31 [3·1%] vs 16 [1·6%]; p=0·019), and decreased rates of grade 3–4 
neutropenia (147 [14·9%] vs 433 [44·0%]; p<0·0001). Addition of fl uorouracil led to increased rates of grade 3–4 
neutropenia (354 [34·5%] of 1025 patients on FEC-P vs 250 [24·2%] of 1032 patients on EC-P; p<0·0001), fever 
(nine [0·9%] vs two [0·2%]), nausea (47 [4·6%] vs 28 [2·7%]), and vomiting (32 [3·1%] vs 15 [1·4%]).
Interpretation In patients with node-positive early breast cancer, dose-dense adjuvant chemotherapy improved 
disease-free survival compared with standard interval chemotherapy. Addition of fl uorouracil to a sequential EC-P 
regimen was not associated with an improved disease-free survival outcome.
Funding Bristol-Myers Squibb, Pharmacia, and Dompè Biotec. 
Introduction
Chemotherapy regimens that combine anthracyclines 
and taxanes improve the outcome of patients with early-
stage breast cancer.1 The most widely used anthracycline-
based regimens in sequential combinations with taxanes 
are doxorubicin and cyclophosphamide (AC) or 
epirubicin and cyclophosphamide (EC) and fl uorouracil, 
doxorubicin, and cyclophosphamide (FAC) or fl uoro-
uracil, epirubicin, and cyclophosphamide (FEC). The 
contribution of fl uorouracil to the anthracycline-
cyclophospamide regimens (AC or EC) has not been 
defi ned.
Various randomised trials2–5 attempted to assess the 
role of dose-dense chemotherapy in patients with early-
stage breast cancer. Most of these trials had important 
diﬀ erences between the dose-dense and control groups 
in terms of number of cycles, dose size, type of drug, and 
total dose, thus rendering interpretation of which 
variable contributed to the observed results diﬃ  cult. The 
few randomised trials with an adequate study design,6–8 
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that is, trials that assessed the same drugs and doses in 
the dose-dense and control groups, reported confl icting 
results. Therefore, the role of dose-dense adjuvant 
chemotherapy in patients with early-stage breast cancer 
is still controversial.9,10 We aimed to establish whether an 
FEC followed by paclitaxel (FEC-P) regimen would 
improve disease-free survival compared with the same 
regimen without fl uorouracil (EC-P) and whether the 
dose-dense schedule would improve disease-free survival 
compared with a standard-interval schedule.
Methods
Study design and patients
This study was a multicentre, open-label, randomised 
phase 3 trial, with a 2 × 2 factorial design aiming to 
address both the role of the addition of fl uorouracil to the 
chemotherapy with epirubicin, cyclophosphamide, and 
paclitaxel and the role of the dose-dense schedule in the 
adjuvant treatment of patients with node-positive breast 
cancer. This study was done in 81 Italian centres by the 
Gruppo Italiano Mammella (GIM). Women were eligible 
if they met the following criteria: histologically proven 
unilateral operable invasive breast cancer confi ned to the 
breast and ipsilateral axilla, primary surgery with 
lumpectomy or total mastectomy plus axillary nodal 
dissection, histological evidence of tumour in at least one 
axillary lymph node, age 18 to 70 years, Eastern 
Cooperative Oncology Group performance status of 1 or 
lower, normal organ and bone marrow functions, and 
use of adequate contraception methods for potentially 
fertile women. Patients had to be randomly assigned 
within 5 weeks of the date of their last surgery. Oestrogen 
and progesterone receptor (ER/PR) positive tumours 
were defi ned by a fi nding of at least 10% of positive cells 
by immunohistochemical analysis. HER2 positive 
tumours were defi ned by a fi nding of at least 10% of 
tumour cells with HER2 protein expression assessed by 
an immunohistochemistry assay or by a positivity of an 
in-situ hybridisation assay.
The study was coordinated by GIM group, who were 
responsible for the study design, randomisation, 
collection and management of data, medical review, data 
analysis, and reporting. The full study protocol is 
available online. The study was approved by ethics 
committees of all participating institutions. Written 
informed consent was obtained from all patients before 
study entry.
Randomisation and masking
Eligible patients were randomly allocated in a 1:1:1:1 ratio 
to one of the four study groups. In fi ve centres, which 
refused the randomisation to the dose-dense treatment 
group, allocations were only to two groups in a 1:1 ratio 
(standard interval EC-P and standard interval FEC-P). 
The four study groups were the following (fi gure 1): four 
cycles of standard-interval intravenous EC (epirubicin 
90 mg/m², cyclophosphamide 600 mg/m², on day 1, 
every 3 weeks [standard-interval chemotherapy]) followed 
by four cycles of intravenous paclitaxel 175 mg/m² on 
day 1, every 3 weeks (q3EC-P group); four cycles of 
standard-interval intravenous FEC (fl uorouracil 
600 mg/m², epirubicin 90 mg/m², cyclophosphamide 
600 mg/m², on day 1, every 3 weeks) followed by four 
cycles of intravenous paclitaxel 175 mg/m² on day 1, every 
3 weeks, (q3FEC-P group); dose-dense EC-P regimen, 
with the same doses and drugs as the q3EC-P group, but 
administered every 2 weeks (dose-dense chemotherapy; 
q2EC-P group); and the dose-dense FEC-P regimen, with 
the same doses and drugs as the q3FEC-P group, but 
given every 2 weeks (q2FEC-P). Randomisation was done 
by a centralised, interactive internet-based system that 
after a summary check of patient’s eligibility, generated 
the random allocation. The only stratifi cation factor was 
centre: within each centre, permuted blocks of size 12 in 
random sequence were used (block size was four in the 
fi ve centres that randomised only to FEC-P vs EC-P). We 
used an open-label design because the procedures 
needed to mask the diﬀ erences between the treatment 
groups in the timing of treatment administration (every 
2 vs every 3 weeks) were not deemed acceptable from an 
ethical viewpoint.
Procedures
Patients enrolled in the q2 groups receiving treatment 
every 2 weeks also received subcutaneous pegfi lgrastim 
(6 mg) 24 h after chemotherapy. Because of the 
occurrence of early leucocytosis (white blood cells in the 
blood >50 cells per mL), an amendment in March, 2004, 
needed the provision of pegfi lgrastim 72 h after 
chemotherapy. Chemotherapy dose reductions and 
delays for clinically signifi cant grade 3 or 4 haematological 
and non-haematological toxic eﬀ ects were done according 
to protocol-defi ned criteria. After completion of 
chemotherapy, patients with hormone-receptor-positive 
tumours received endocrine therapy. After the approval 
of adjuvant trastuzumab for HER2 positive early breast 
cancer, an amendment, in April, 2006, needed 
trastuzumab treatment for 1 year after the completion of 
chemotherapy for all patients with HER2 positive 
tumours. Radiation therapy after completion of 
chemotherapy was mandatory for patients who had a 
lumpectomy. For patients who had a mastectomy, 
radiation therapy was done according to each 
participating institution guidelines.
Outcomes
The two primary comparisons were between FEC-P and 
EC-P, and between dose-dense and standard-interval 
chemotherapy. The primary study endpoint was disease-
free survival; secondary endpoints included overall 
survival and safety.
Disease-free survival was computed from the date of 
randomisation to the date of local recurrence, distant 
metastases, contralateral or ipsilateral breast tumour 
For the protocol see http://www.
oncotech.org/gim2
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(excluding ductal carcinoma in situ), second primary 
malignancy, death from any cause, and loss to follow-up 
or end of study, whichever came fi rst. Disease-free 
survival times of patients without a disease-free survival 
event when lost to follow-up or at the time of study 
closure were censored on the date of the last contact. The 
defi nition of disease-free survival corresponds to the 
Invasive Disease Free Survival defi ned by Hudis and 
colleagues.11 Similarly, overall survival was computed 
from the day of randomisation to the date of death from 
any cause, loss to follow-up, or the end of study.
Adverse events were assessed clinically and by 
haematological and biochemical measurements 
throughout chemotherapy. Adverse events were graded 
according to the National Cancer Institute common 
toxicity criteria version 2.0.12
Statistical analysis
Our power calculations, based on previous data,13 
assumed a 5 year disease-free survival of about 75% in 
the control group (q3EC-P). Furthermore, we assumed 
that the minimum therapeutic eﬀ ect worth detecting in 
this study, in view of the increased toxic eﬀ ects associated 
with the experimental treatments, was a 20% relative 
reduction in disease-free survival (hazard ratio 
[HR]=0·80), corresponding to a 4·4% absolute increase 
in 5-year disease-free survival. To detect with an 80% 
power and a signifi cance 5% (two-sided), a 20% relative 
reduction in the risk of relapse in either comparison 
(EC-P vs FEC-P and dose-dense vs standard interval 
chemotherapy), 635 disease-free survival events had to be 
observed. We estimated that to observe 635 events, 
1500 patients needed to be enrolled, with an average 
Figure 1: Trial profi le
q3=standard interval chemotherapy. q2=dose-dense chemotherapy. EC-P= epirubicin, and cyclophosphamide, followed by paclitaxel. FEC-P=fl uorouracil, epirubicin, 
and cyclophosphamide, followed by paclitaxel.
2091 patients randomly assigned
545 assigned to q3EC -P 
545 analysed for endpoint
EC-P versus FEC-P comparison Standard interval versus dose dense comparison
1047 treated with EC-P
544 analysed for endpoint
1044 treated with  FEC-P
502 analysed for endpoint
1089 treated with 
 standard interval
 regimens
88 randomly assigned in
 the 2-group study
500 analysed for endpoint
1001 treated with 
 standard interval
 regimens
1002 treated with dose 
 dense regimens
476 completed 8 cycles
 of treatment
483 completed 8 cycles
 of treatment
451 completed 8 cycles
 of treatment
441 completed 8 cycles
 of treatment
544 assigned to q3FEC-P 502 assigned to q2EC-P 500 assigned to q2FEC-P
7 did not receive treatment
 2 refused
 5 other causes
11 did not receive treatment
 0 refused
 11 other causes
5 did not receive treatment
 3 refused
 2 other causes
8 did not receive treatment
 2 refused
 6 other causes
 51 discontinued treatment
 27 adverse event
 1 early relapse
 10 refused
 13 other causes
 46 discontinued treatment
 23 adverse event
 0 early relapse
 13 refused
 10 other causes
 50 discontinued treatment
 26 adverse event
 2 early relapse
 10 refused
 12 other causes
 62 discontinued treatment
 23 adverse event
 5 early relapse
 14 refused
 20 other causes
Articles
1866 www.thelancet.com   Vol 385   May 9, 2015
follow-up of 7–8 years, or 2000 patients with an average 
follow-up of 5·5–6 years. We planned the fi nal analysis 
once we had observed 635 events. No formal intermediate 
analyses were planned. However, in March, 2013, 10 years 
after the enrolment of the fi rst patient, the Steering 
Committee of the study, in view of the fact that the study 
had enrolled 2091 patients that had been followed for a 
median of 7·0 years, and that, so far, the total number of 
disease-free survival events was still close to 500, decided 
to proceed with the fi nal analysis of the study and to 
publish its results, because to wait the 2 or more years 
that would have been necessary to achieve the target 
number of 635 events was not deemed appropriate. This 
decision was based only on information about the event 
rates in the four treatment groups combined, and was 
entirely masked to treatment-specifi c data and results, 
thereby avoiding any bias related to an unplanned 
interim analysis. On the basis of the fi nal number of 
events recorded at the closing date (521 events; May 9, 
2013), the power to detect the target HR of 0·80 was 
decreased to 72%, whereas an 80% power was available 
for a HR of 0·785.
The two primary comparisons were between FEC-P 
and EC-P, and between dose-dense and standard-interval 
chemotherapy. All statistical analyses were done on an 
intention-to-treat basis and all protocol violators were 
analysed within their randomised groups.
The presence of an interaction between the two study 
factors (FEC-P vs EC-P) and dosing every 2 weeks vs every 
3 weeks) was assessed by fi tting two multivariate Cox 
models to the data, one for disease-free survival and the 
other for overall survival. Only patients enrolled in 
centres that randomised to all four treatment groups 
were included in these analyses. In each of these two 
models, only three factors were included, the two 
treatment assignments (dosing type and dosing 
frequency) and the interaction term between them. The 
signifi cance of the interaction between the two 
treatments was assessed by means of a backward 
procedure, based on the likelihood ratio test.
The two primary study hypotheses were tested 
independently by comparison of disease-free survival in 
the groups of patients assigned to EC-P with those assigned 
to FEC-P, and comparison of those in the 2 weeks group 
with those in the 3 weeks group. We used a stratifi ed log-
rank test to assess the signifi cance of the diﬀ erences 
between the disease-free survival curves, where the 
stratifi cation factor for the EC-P versus the FEC-P 
comparison was the assignment to 2 week or 3 week 
dosing, whereas for the comparison between dose-dense 
versus standard-interval chemotherapy, the stratifi cation 
factor was assignment to EC-P or FEC-P. In all analyses 
focused on dose-density, we excluded patients enrolled to 
the fi ve centres that randomised only to standard-interval 
EC-P and standard-interval FEC-P and did not randomise 
to dose schedule. The same procedures were used in the 
analyses of overall survival.
Kaplan-Meier product-limit estimators were plotted to 
describe disease-free survival and overall survival in EC-P 
and FEC-P groups, adding together patients in the dose 
schedule groups, and for q2 and q3 groups, adding 
together patients in the two drug groups.
To provide estimates of treatment eﬀ ects adjusted for 
potential confounding factors, and to assess the 
consistency of these estimates across strata of these factors 
(subgroup analyses), we fi tted several multivariate Cox 
q3EC-P group 
(n=545)
q3FEC-P group 
(n=544)
q2EC-P group 
(n=502)
q2FEC-P group 
(n=500)
Age at study entry, years 51 (43–60) 53 (45–61) 53 (44–59) 51 (44–59)
Menopausal status
Premenopausal 281 (52%) 245 (45%) 232 (46%) 263 (53%)
Postmenopausal 264 (48%) 299 (55%) 270 (54%) 237 (47%)
Type of surgery
Lumpectomy 338 (62%) 320 (59%) 298 (59%) 313 (63%)
Mastectomy 207 (38%) 224 (41%) 204 (41%) 187 (37%)
Tumour size
T1 283 (52%) 262 (48%) 262 (52%) 253 (51%)
T2 218 (40%) 233 (43%) 202 (40%) 208 (42%)
T3 21 (4%) 25 (5%) 25 (5%) 29 (6%)
T4 19 (3%) 23 (4%) 10 (2%) 9 (2%)
Unknown 4 (1%) 1 (<1%) 3 (1%) 1 (<1%)
Number of positive nodes
1–3 327 (60%) 319 (59%) 319 (64%) 284 (57%)
4–9 135 (25%) 136 (25%) 116 (23%) 135 (27%)
≥10 83 (15%) 89 (16%) 67 (13%) 81 (16%)
Unknown 1 (<1%) 1 (<1%) 0 0
Tumour grade
G1 30 (5%) 21 (4%) 35 (7%) 30 (6%)
G2 236 (43%) 238 (44%) 225 (45%) 240 (48%)
G3 270 (49%) 266 (49%) 229 (46%) 214 (43%)
Unknown 9 (2%) 19 (3%) 13 (3%) 16 (3%)
Expression of HER2 protein
Positive 123 (23%) 131 (24%) 105 (21%) 121 (24%)
Negative 344 (63%) 332 (61%) 318 (63%) 299 (60%)
Unknown 78 (14%) 81 (15%) 79 (16%) 80 (16%)
Expression of hormone receptors
ER or PR positive 420 (77%) 442 (81%) 407 (81%) 401 (80%)
ER and PR negative 103 (19%) 88 (16%) 83 (16%) 85 (17%)
Unknown 22 (4%) 14 (3%) 12 (2%) 14 (3%)
KI67 value (% of positive cells)
0–14 120 (22%) 113 (21%) 142 (28%) 132 (26%)
15–20 33 (6%) 51 (9%) 44 (9%) 41 (8%)
>20 273 (50%) 269 (49%) 214 (43%) 232 (46%)
Unknown 119 (22%) 111 (20%) 102 (20%) 95 (19%)
Data are median (IQR) or n (%). q3EC-P=standard-interval chemotherapy with epirubicin and cyclophosphamide, 
followed by paclitaxel. q3FEC-P=standard-interval chemotherapy with fl uorouracil, epirubicin, and cyclophosphamide, 
followed by paclitaxel. q2EC-P=dose-dense chemotherapy with epirubicin and cyclophosphamide, followed by 
paclitaxel. q2FEC-P=dose-dense chemotherapy with fl uorouracil, epirubicin, and cyclophosphamide, followed by 
paclitaxel. HER2=human epidermal growth factor receptor 2. ER=oestrogen receptor. PR=progesterone receptor. 
Ki67=Ki67 labelling index. 
Table 1: Baseline characteristics
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disease-free survival and overall survival models to the 
data. These analyses were done separately for the FEC-P 
versus EC-P and for the 3 week and 2 week comparisons.
The following covariates were included in the models: 
age, menopausal status, type of surgery, histological type, 
tumour size, nodal status, grade, HER2 status, and 
hormonal receptors. In a substantial proportion of patients 
(57 [3%] patients) the information about the grade of the 
primary tumour was missing. To avoid the exclusion from 
all multivariate analyses, the grade of these patients was 
reclassifi ed, according to the procedure reported in the 
appendix.
For subgroup analyses, the interaction terms between 
the treatment group and each of the prognostic factors 
were introduced in the model one at a time. The statistical 
signifi cance of the interaction term was then assessed by 
a backward procedure based on the likelihood ratio test. 
Proportionality was tested with Schoenfeld residuals.
The same procedures were repeated for the subgroup 
analyses of overall survival. Because of the absence of any 
correction for multiple testing, and the fact that no 
subgroup analysis was anticipated in the study protocol, 
the results of these analyses (ie, tests for interactions) are 
to be thought of as merely exploratory and any signifi cant 
results must be considered with caution. Forest plots 
were used to summarise the results of various subgroup 
analyses. All reported p values are two-sided. We used 
SPSS version 20.0 for all statistical analyses. This trial is 
registered with ClinicalTrials.gov, number NCT00433420.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. LDM, SDP, and the statistician (PB) 
had full access to all of the data and had fi nal responsibility 
for the decision to submit the manuscript for publication.
Results
Between April 24, 2003 and July 3, 2006, 2091 patients 
entered the study. Of these, 2003 patients were randomly 
assigned to four treatment groups, while 88 were 
randomly assigned only to q3FEC-P and q3EC-P 
(fi gure 1). The treatment groups were well balanced with 
respect to demographic and tumour characteristics 
(table 1).
The planned number of chemotherapy cycles was 
completed by almost 90% of patients in every group 
(fi gure 1). The relative dose-intensity was 99% in the 
q3EC-P group, 98% in the q3FEC-P group, 98% in the 
q2EC-Pgroup, and 98% in the q2FEC-P group (a 
complete summary of treatment compliance and dose-
intensity is provided in the appendix). Patients with 
HER2-positive disease who were enrolled after the 
approval of adjuvant trastuzumab in April, 2006, received 
trastuzumab for 1 year; overall 130 (27%) of 480 patients 
with HER2-positive tumours received trastuzumab: 
40 (33%) patients in the q3EC-P group, 32 (24%) in the 
q3FEC-P group, 26 (25%) in the q2EC-P group, and 
32 (26%) in the q2FEC-P group.
As of May 9, 2013, after a median follow-up of 7·0 years 
(IQR 4·5–6·3), 521 (25% of patients) disease-free survival 
events occurred in the overall study population. 266 (13%) 
deaths occurred in total (table 2). No interaction was seen 
between the eﬀ ect of two randomisation variables (FEC-P 
vs EC-P and dense vs standard-interval dosing) on 
disease-free survival (pinteraction=0·628) or overall survival 
(pinteraction=0·889), making it possible to analyse the two 
study factors independently.
270 disease-free survival events occurred in the two 
FEC-P groups combined and 251 occurred in the two 
EC-P groups combined. The estimated rates of disease-
free survival at 5 years were 78% (95% CI 75–81) in the 
FEC-P group and 79% (76–82) in the EC-P group 
(p=0·561; fi gure 2). Overall survival rates at 5 years were 
91% (89–93) in the FEC-P group and 92% (90–94) EC-P 
group (p=0·234; fi gure 2). The similar outcome between 
patients assigned to FEC-P and EC-P was confi rmed in 
multivariate analyses, where the comparisons between 
FEC-P and EC-P were adjusted for prognostic factors 
(HR for disease-free survival 1·02, 95% CI 0·86–1·22, 
p=0·812 and for overall survival (1·07; 0·84–1·37, 
p=0·578; data not shown).
In subgroup analyses (appendix), no evidence of 
interaction was observed between FEC-P or EC-P and any 
factor, with the exception of nodal status, for which a 
signifi cant interaction was seen (p=0·011) for disease-free 
survival only. However, the interaction was attributable to 
the diﬀ erence in favour of the EC-P group observed in 
patients with 4–9 aﬀ ected lymph nodes, without any 
discernible trend of increasing or decreasing HR.
224 disease-free survival events occurred in the two 
groups given chemotherapy every 2 weeks and 270 in the 
two groups given chemotherapy every 3 weeks. The 
estimated rates of disease-free survival at 5 years were 
81% (95% CI 79–84) in the dose dense group and 76% 
(74–79) in the standard interval groups (p=0·004; fi gure 2).
q3EC-P group 
(n=545)
q3FEC-P group 
(n=544)
q2EC-P group 
(n=502)
q2FEC-P group 
(n=500)
Disease-free survival events* 140 (26%) 157 (29%) 111 (22%) 113 (23%)
Breast cancer relapse 121 (22%) 138 (25%) 94 (19%) 93 (19%)
Locoregional alone 13 (2%) 18 (3%) 10 (2%) 12 (2%)
Distant 93 (17%) 102 (19%) 74 (15%) 74 (15%)
Concurrent distant and locoregional 11 (2%) 13 (2%) 8 (2%) 5 (1%)
Unknown site 4 (1%) 5 (1%) 2 (<1%) 2 (<1%)
Second primary malignancy 19 (3%) 15 (3%) 12 (2%) 16 (3%)
Primary breast cancer 7 (1%) 11 (2%) 4 (1%) 6 (1%)
Second primary tumour, non-breast 12 (2%) 4 (1%) 8 (2%) 10 (2%)
Death without evidence of relapse 0 4 (1%) 5 (1%) 4 (1%)
Overall survival events† 75 (14%) 88 (16%) 48 (10%) 55 (11%)
Data are n (%). *Only fi rst events are considered. †Overall survival events denote death from any cause.
Table 2: Disease-free survival and overall survival events in the intention-to-treat population
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Overall estimated survival rates at 5 years were 94% 
(93–96) in the dose dense group and 89% (87–91) in the 
standard interval group (p=0·001; fi gure 2). These 
diﬀ erences were confi rmed in multivariate analyses, in 
which the comparisons between dose times were 
adjusted for prognostic factors (HR for disease-free 
survival 0·78; 0·65–0·94, p=0·008 and HR for overall 
survival 0·66; 0·51–0·85, p=0·002; data not shown).
A remarkable consistency in the diﬀ erence between 
2 week and 3 week dosing was observed in subgroup 
analyses of disease-free survival (appendix). No 
signifi cant interaction was seen between type of regimen 
and any of the prognostic factors. In subgroup analyses 
of overall survival (appendix), a signifi cant interaction 
was observed between treatment assignment and tumour 
size (p=0·043), with no eﬀ ect seen in patients with pT1 
tumours (HR 0·98). No noteworthy variation in the HRs 
was observed in other subgroups considered.
The eﬀ ect of 2 week or 3 week dosing on disease-free 
survival did not diﬀ er according to hormone-receptor 
status (HR=0·80, 95% CI 0·65–0·98 in hormone-receptor-
positive patients; HR=0·69, 0·48–0·99 in hormone-
receptor-negative patients; pinteraction=0·43; appendix). For 
hormone-receptor positive patients, the 5 year disease-
free survival was 83% (81–86) with the dose dense 
schedule and 80% (77–83; p=0·033) with the standard 
interval schedule; and for hormone-receptor negative 
patients, 71% (64–78) with the dose dense schedule and 
61% (53–69; p=0·046) in with the standard interval 
schedule (fi gure 3). The eﬀ ect of the schedule on overall 
survival was similar in hormone-receptor-positive (HR 
0·69, 0·51–0·94) and hormone-receptor-negative 
patients (HR 0·55, 0·34–0·90; pinteraction=0·423).
No signifi cant interaction occurred between tras tuzumab 
therapy and the eﬀ ect of the dose-dense schedule 
(pinteraction=0·728 for disease-free survival and pinteraction=0·679 
Figure 2: Disease-free survival and overall survival
Kaplan-Meier estimates of disease-free survival (A) and overall survival (B) in EC-P and FEC-P groups. Kaplan-MeIer estimates of disease-free survival (C) and overall survival (D) in dose-dense and 
standard interval chemotherapy groups. EC-P=epirubicin, and cyclophosphamide, followed by paclitaxel. FEC-P=fl uorouracil, epirubicin, and cyclophosphamide, followed by paclitaxel.
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for overall survival) even though, in the subgroup of 
patients with HER2-positive tumours treated with 
trastuzumab, the eﬀ ect of dose dense therapy was smaller 
(HR 0·99; 95% CI 0·49–1·99 for disease-free survival and 
HR 0·93 0·35–2·54 for overall survival). Subgroup 
analyses according to HER2 status and treatment with 
trastuzumab are shown in the appendix.
Table 3 shows major (occurring in at least 5% of the 
population) toxic eﬀ ects that occurred in the four 
groups. Grade 3–4 toxic eﬀ ects that occurred in the 
standard interval and dose-dense groups are reported 
in the appendix. Patients receiving dose-dense 
chemotherapy, compared with those treated with q3 
regimens, more frequently had grade 3–4 anaemia (14 
[1·4%] of 988 patients vs two [0·2%] of 984 patients; 
p=0·002), transaminitis (19 [1·9%] vs four [0·4%]; 
p=0·001), and myalgias (31 [3·1%] vs 16 [1·6%], 
p=0·019), and less frequently had grade 3–4 neutropenia 
(147 [14·9%] vs 433 [44·0%]; p<0·0001). The appendix 
shows grade 3–4 toxic eﬀ ects that occurred in the EC-P 
and FEC-P groups. Grade 3–4 neutropenia, fever, 
nausea, and vomiting were signifi cantly more frequent 
in patients treated with FEC-P than in patients treated 
with EC-P. We noted one case of acute myeloid 
leukaemia and one case of myelodysplastic syndrome, 
both in the q2EC-P arm.
No treatment-related deaths occurred. Five patients 
(two patients in the q3EC-P group, one in the q3FEC-P 
group, one in the q2EC-P group, and one in the q2FEC-P 
group) died from early tumour recurrence within 1 year 
of randomisation.
Discussion
This trial shows that, in women with node-positive breast 
cancer, the sequential treatment regimen FEC-P did not 
improve disease-free survival compared with the same 
regimen without fl uorouracil (EC-P), whereas the dose-
dense regimen was associated with a signifi cant 
reduction in the risk of recurrence and death compared 
with standard-interval chemotherapy.
Both AC/EC and FAC/FEC14 are widely used in the 
sequential treatment regimens with anthracycline-
containing chemotherapy and taxanes, and no data are 
available so far to support the choice between the 
treatment with or without fl uorouracil. The fi ndings of 
this trial suggest that, at least in sequential regimens 
with anthracyclines and paclitaxel, the addition of 
fl uorouracil to the EC-P regimen was associated with an 
increase in toxic eﬀ ects (grade 3–4 neutropenia, fever, 
nausea, and vomiting) whereas we observed no 
additional outcome benefi ts. Although, the role of 
fl uorouracil in the adjuvant treatment of early breast 
cancer cannot be completely discarded, the lack of 
eﬃ  cacy noted in our study raises a general question on 
the opportunity to include it in modern adjuvant 
chemotherapy regimens, especially if the increase in 
toxic eﬀ ects associated with its use is taken into account.
An important fi nding of this study is that the provision 
of dose-dense chemotherapy was associated with a 
signifi cant and clinically relevant disease-free survival 
and overall survival benefi t compared with standard 
interval chemotherapy: the observed reduction from 24% 
to 19%, in the cumulative 5-year risk of invasive disease 
or death, corresponds to a hazard ratio of 0·78. Even 
more impressive was the eﬀ ect on overall survival, for 
which we observed a reduction in 5-year cumulative 
mortality from 11% to 6%, for a hazard ratio of 0·66.
The role of dose-dense chemotherapy, as adjuvant 
treatment for patients with breast cancer, was assessed in 
various phase 3 studies, but the most of these trials 
compared dose-dense chemotherapy with regimens that 
use standard intervals but with diﬀ erent drugs or dose in 
the treatment groups, thus making diﬃ  cult to extrapolate 
the true role of a dose-dense strategy.2–5 Few studies6–8 
Figure 3: Disease-free survival according to hormone-receptor status
(A) Kaplan-Meier estimates of disease-free survival in hormone-receptor positive patients treated with 
dose-dense chemotherapy or standard-interval chemotherapy. (B) Kaplan-MeIer estimates of disease-free 
survival in hormone-receptor negative patients treated with dose-dense chemotherapy or standard-interval 
chemotherapy. EC-P=epirubicin, and cyclophosphamide, followed by paclitaxel. FEC-P=fl uorouracil, epirubicin, 
and cyclophosphamide, followed by paclitaxel. 
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compared the same chemotherapy regimen administered 
every 2 or every 3 weeks. A dose-dense chemotherapy 
approach using concurrent doxorubicin and 
cyclophosphamide followed by paclitaxel was assessed in 
the Cancer and Leukaemia Group B 9741 trial, 6 which 
showed a signifi cant improvement in disease-free survival 
and overall survival for the dose-dense chemotherapy 
group. The Italian Gruppo Oncologico Nord Ovest-
Mammella Intergruppo Trial assessed the dose-dense 
approach in a non-taxane-based regimen. Although 
numerically improved outcome in the dose-dense group 
was observed, the diﬀ erence was not statistically 
signifi cant.7 The UK TACT2 trial, 8 so far presented only in 
abstract form, compared standard chemotherapy with 
epirubicin followed by CMF (cyclophosphamide, 
methotrexate, fl uorouracil) or capecitabine to dose-dense 
epirubicin and, at a median follow-up of 49 months, 
showed no diﬀ erence in disease-free survival between the 
two treatment strategies. The pooled analysis of 
randomised trials showed that dose-dense chemotherapy 
results in better overall and disease-free survival.10 
However, because of the paucity of randomised controlled 
trials with an adequate design, additional data from 
randomised trials were claimed to be necessary to better 
clarify the role of dose-dense chemotherapy. Our fi ndings 
underline the results of the CALGB B9741 trial and support 
the clinically relevant benefi t associated with the dose-
dense strategy in regimens based on the sequential 
provision of anthracycline-containing chemotherapy 
followed by paclitaxel. In the CALBGB trial, dose-dense 
chemotherapy was particularly eﬀ ective in patients with 
hormone-receptor-negative breast cancer, whereas the 
benefi t in hormone-receptor-positive patients was smaller 
and not signifi cantly diﬀ erent from that observed with 
standard-interval chemotherapy.15 Our results, instead, 
show that the benefi ts of dose-dense chemotherapy are 
present in hormone-receptor-positive patients as well. 
However, because of the underrepresentation of hormone 
receptor-negative patients (only 17% of the overall study 
population) in our study, the statistical power of the test for 
interaction between hormone receptor status and dose-
density was limited, and then a diﬀ erence in the magnitude 
of benefi t of dose-dense chemotherapy in the two groups 
of patients (hormone receptor-positive and hormone 
receptor-negative) cannot be completely ruled out.
q3EC-P group (n=536) q3FEC-P group (n=533) q2EC-P group (n=496) q2FEC-P group (n=492)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Anaemia 264 (49%) 0 263 (49%) 2 (<1%) 329 (66%) 6 (1%) 321 (65%) 8 (2%)
Neutropenia 153 (29%) 200 (37%) 103 (19%) 257 (48%) 69 (14%) 50 (10%) 61 (12%) 97 (20%)
Thrombocytopenia 29 (5%) 2 (<1%) 40 (8%) 2 (<1%) 57 (11%) 1 (<1%) 86 (17%) 5 (1%)
Asthenia 275 (51%) 5 (1%) 286 (54%) 12 (2%) 294 (59%) 13 (3%) 294 (60%) 15 (3%)
Diarrhoea 79 (15%) 1 (<1%) 69 (13%) 2 (<1%) 77 (16%) 2 (<1%) 94 (19%) 3 (1%)
Bone pain 200 (37%) 10 (2%) 198 (37%) 11 (2%) 263 (53%) 11 (2%) 234 (48%) 20 (4%)
Fever 91 (17%) 1 (<1%) 103 (19%) 5 (1%) 131 (26%) 1 (<1%) 127 (26%) 4 (1%)
Myalgia 248 (46%) 9 (2%) 242 (45%) 8 (2%) 237 (48%) 15 (3%) 236 (48%) 16 (3%)
Stomatitis 164 (31%) 0 208 (39%) 3 (1%) 180 (36%) 4 (1%) 189 (38%) 5 (1%)
Nausea 390 (73%) 13 (2%) 374 (70%) 22 (4%) 365 (74%) 15 (3%) 345 (70%) 25 (5%)
Vomiting 199 (37%) 8 (1%) 197 (37%) 12 (2%) 203 (41%) 7 (1%) 210 (43%) 20 (4%)
Neuropathy 269 (50%) 16 (3%) 269 (50%) 12 (2%) 232 (47%) 19 (4%) 233 (47%) 16 (3%)
Transaminase elevation 130 (24%) 3 (1%) 159 (30%) 2 (<1%) 174 (35%) 11 (2%) 196 (40%) 8 (2%)
Comparison between EC-P and FEC-P in terms of grade 3–4 toxicity is reported in the appendix. Comparison between dose dense and standard interval regimens in terms 
of grade 3–4 toxic eﬀ ects is reported in the appendix. 
Table 3: Adverse events occurring in at least 5% of any one group
Panel: Research in context
Systematic review
We searched PubMed for articles about dose-dense regimens and fl uorouracil in the 
adjuvant treatment of breast cancer without language or date restriction. Additionally, 
we searched the abstract of major oncology congresses. A pooled analysis10 of randomised 
trials showed that chemotherapy regimens with an increased dose-density are associated 
with an improved overall survival and disease-free survival. However, in most studies 
diﬀ erences were reported between the dose-dense and control groups in terms of 
number of cycles, dose size, type of drugs and total dose, thus making interpretation of 
which variable contributed to the observed results diﬃ  cult.2–5 Of the few randomised 
studies with an adequate design to specifi cally address the role of dose-dense, the CALGB 
B9741 study6 showed a benefi t of dose-dense chemotherapy, mainly restricted to 
hormone-receptor-negative tumours; 15 the GONO-MIG trial7 showed a trend toward a 
benefi t of dose-dense adjuvant chemotherapy, and, conversely, results from the UK 
TACT2 trial8 showed no benefi t of this chemotherapy schedule. The GIM2 trial, beside 
assessment of the role of dose-density, was unique in addressing the role of the addition 
of fl uorouracil to the chemotherapy regimen with anthracycline-cyclophosphamide 
followed by paclitaxel.
Interpretation
This GIM2 trial supports the increased eﬃ  cacy of dose-dense chemotherapy and suggests 
that the benefi t is present in both hormone-receptor-negative and hormone-receptor-
positive tumours. Our results fi rst show that the addition of fl uorouracil to anthracycline 
and cyclophosphamide followed by paclitaxel is not associated with an improved 
outcome compared with the same treatment without fl uorouracil.
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The outcome improvement observed in hormone-
receptor-positive patients might be due to the longer 
follow-up (median 7·0 years [IQR 4·5–6·3]) of our study 
compared than in other studies.15 In fact, the pattern of 
risks over time is diﬀ erent in hormone-receptor-negative 
and hormone-receptor-positive patients: in the fi rst few 
years after surgery the risk of relapse is high in hormone-
receptor-negative patients and very low in hormone-
receptor-positive patients, in whom a substantial number 
of events are observed after the fi fth year. This pattern of 
recurrence suggests that a long follow-up is necessary to 
observe the potential benefi t of adjuvant treatment in 
hormone-receptor-positive patients.
Because of the small proportion of patients with HER2-
positive tumours treated with trastuzumab, no signifi cant 
interaction was seen between trastuzumab therapy and 
the eﬀ ect of the dose-dense schedule. However, the lack 
of a clear eﬀ ect in patients with HER2-positive tumours 
treated with trastuzumab suggests that the eﬃ  cacy of 
dose-dense chemotherapy might be less noticeable or 
absent in this subgroup of patients.
The main limitation to the generalisability of the dose-
dense regimen tested in the present study might be the 
schedule of paclitaxel. At the time the study was planned, 
paclitaxel at the dose of 175 mg/m² every 3 weeks, was the 
standard schedule in the adjuvant treatment of breast 
cancer. The demonstration that weekly paclitaxel is more 
eﬀ ective than the every 3 weeks schedule, only came in 
2008, 2 years after the end of recruitment in our trial.16 
Since then, the 3 weekly paclitaxel is no longer a standard 
treatment and has been replaced by 12 cycles of weekly 
paclitaxel. Nevertheless, recent results from the SWOG 
S0221 phase 3 trial showed that dose-dense paclitaxel, 
given every 2 weeks, is similar, in terms of both disease-
free survival and overall survival, to weekly paclitaxel and 
then, that either dose-dense and weekly regimen are 
acceptable schedules of paclitaxel administration.17 Yet, in 
that study, grade 3–4 toxic eﬀ ects were higher with the 
dose-dense administration than with weekly administration 
of paclitaxel, thus suggesting that weekly paclitaxel might 
be a better option than dose-dense paclitaxel.
An additional limitation of our trial is that the study 
design does not allow separation between the eﬀ ect of 
dose-dense (F)EC vs dose-dense paclitaxel, leaving the 
possibility that the intensifi cation of either (F)EC or 
paclitaxel might be suﬃ  cient to obtain the full benefi t 
observed with the whole dose-dense regimen. Moreover, 
no correction for multiple testing was planned to 
account fo the 2 primary analyses conducted in this trial 
(FEC-P vs EC-P and q2 vs q3), since this correction is not 
considered necessary in factorial trials.18 At any rate, the 
use of a stricter (eg, p=0·0253 using the Bonferroni 
correction) criterion for statistical signifi cance would not 
change the interpretation of either comparison.
Dose-dense chemotherapy was confi rmed to be more 
toxic than standard-interval chemotherapy, with the 
exception of neutropenia, that, in view of the provision of 
pegfi lgrastim, was less frequent in the dose-dense group. 
The use of pegfi lgrastim is still considered investigational 
in the setting of dose-dense chemotherapy.19 Our data 
showing that pegfi lgrastim, given after 72 h, is safe and 
feasible in dose-dense regimens,20 are supported by 
fi ndings from a prospectively randomised study,21 which 
showed that pegfi lgrastim after 72 h has a similar eﬃ  cacy 
of pegfi lgrastim after 24 h and is associated with a lower 
incidence of grade 3–4 leucopenia. The observed 
incidence of acute myeloid leukaemia and myelo displastic 
syndrome, two cases in 1002 patients (0·19%) treated 
with dose-dense chemotherapy, is similar to that generally 
reported in dose-dense studies22 and should be considered 
in view of the 52 fewer deaths observed in the dose-dense 
groups than in the standard interval groups (panel). 
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